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Abstract 
Mesenchymal stromal cells are present in very low numbers in the bone marrow, 
necessitating their selective expansion on tissue culture plastic prior to their use in tissue 
engineering applications. MSC expansion is laborious, time consuming, unphysiological 
and not economical, thus calling for automated bioreactor-based strategies. We and 
others have shown that osteogenic grafts can be cultured in bioreactors by seeding either 
2D - expanded cells or by direct seeding of the mononuclear fraction of bone marrow. To 
further streamline this protocol, we assessed in this manuscript the possibility to seed the 
cells onto porous calcium phosphate ceramics directly from unprocessed bone marrow. 
Using predetermined volumes of bone marrow from multiple human donors with 
different nucleated cell counts, we were able to grow a confluent cell sheath on the 
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scaffold surface in 3 weeks. Cells of both stromal, endothelial and haematopoietic origin 
were detected, in contrast to grafts grown from 2D expanded cells where only stromal 
cells could be seen. Upon implantation in nude mice, similar quantities of bone tissue 
were generated as compared to that obtained by using the conventional number of culture 
expanded cells from the same donor. We conclude that human osteogenic grafts can be 
efficiently prepared by direct seeding of cells from unprocessed bone marrow. 
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1. Introduction 
Adult mesenchymal stem or stromal cells (MSCs) obtained from bone marrow have great 
potential in tissue engineering applications as they can be easily isolated and  
differentiated into osteogenic, chondrogenic and adipogenic lineages.  [1] [2] [3]. One of 
the many tissue engineering applications is the field of bone defect reconstruction. For 
this application, MSCs are differentiated into osteoblasts in vitro as evidenced by the 
deposition of a mineralized matrix and expression of osteogenic markers such as alkaline 
phosphatase (ALP). They are then implanted in vivo to bridge bone defects [4] [5] [6] 
[7]. However, MSCs represent a rare population of cells  with a reported incidence of 
0.01 to 0.001% within the bone marrow [8] [1] and large numbers are required to heal 
bone defects. For instance, spinal fusion surgery requires a minimum of 4 cc of graft 
material when performed using the anterior interbody fusion method [9]. In our lab, we 
typically use porous calcium phosphate ceramics, 2-3 mm in size with 200,000 cells per 
 3
particle to generate an osteogenic graft. To generate 4 cc of graft material, at least 36 
million cells would be required. The need for such large cell numbers coupled with the 
low frequency of MSCs in bone marrow, necessitates their expansion prior to their use in 
bone tissue engineering and also other applications. Isolation and expansion of MSCs 
relies on their ability to adhere to plastic [10]. When bone marrow is plated onto tissue 
culture plastic, a population of cells is obtained which is referred to as MSCs, based on 
their multipotency and CD expression profile. MSCs are then further expanded to obtain 
a sufficient number of cells to load on scaffolds for tissue engineering applications [3] [6] 
[11].    
 
However, it is well recognized that culturing cells in a monolayer on  plastic, bereft of the 
company of the heterogeneous cell populations normally present within the bone marrow, 
is not physiological. The monolayer culture does not provide an ideal milieu for cell-cell 
and cell-extracellular matrix interactions, thereby limiting the mechanical and 
biochemical cues required for the optimal functioning of the cells [12] [13] [14]. 
 
The number of clonogenic MSCs present in bone marrow varies greatly from donor to 
donor. For instance, we tested 27 donors with varying nucleated counts. On plating the 
aspirates on tissue culture plastic at a density of 500,000 mononuclear cells/cm2 and 
trypsinizing them at 80% confluency, we obtained on average, 4 million MSCs (data not 
shown). As previously mentioned, 9 million cells are required for obtaining 1cc of graft 
material and for clinical application at least 30-40 million cells are required. Thus, in the 
conventional method of tissue engineering using tissue culture plastic, multiple cycles of 
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medium change, cell trypsinizing, counting and replating are required to obtain a 
sufficient number of cells. Semi-automation of the process to engineer bone grafts using 
bioreactor technology is under investigation [14-22]. Here, MSCs are isolated from the 
bone marrow and expanded in 2D to obtain the required numbers. Next, seeding and 
proliferation on scaffolds are performed within the bioreactor. Bioreactors provide a 
closed standardized culture system which requires minimal operator handling and good 
physicochemical environmental control, which is crucial for cell survival and 
proliferation. However, the 2D expansion phase still presents a barrier to complete 
automation. Based on these considerations, researchers have tried to culture bone 
marrow- derived MSCs directly on 3D scaffolds, bypassing the need for the 2D 
expansion phase [23] [24] [25] [26].  The nucleated cells within the bone marrow were 
separated using a density gradient separation method.  Then, mononuclear cells were 
seeded in the bioreactor on scaffolds to grow the cell ceramic constructs. These studies 
demonstrated that osteoinductive grafts could  be generated within an exclusive 3D 
system with results comparable to the conventional 2D method of generating grafts [23] 
[24]. This possibility of expanding MSCs within 3D scaffolds opens new frontiers in the 
streamlining of the process for therapeutic use. 
 
Whereas the mononuclear cell count is typically used to express the cellularity of a bone 
marrow aspirate, it does not accurately represent the number of colony forming units 
(CFU-Fs) contained within the particular marrow [27]. The best predictor of the 
osteogenic capacity of cell-laden scaffold constructs is the estimation of the final number 
of clonogenic MSCs implanted [23]. Cell surface markers such as STRO-1 and nerve 
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growth factor (NGF) receptor may be used to prospectively isolate clonogenic MSCs 
from the crude marrow [28, 29]. However, for cell isolation the marrow is subjected to 
cell separation strategies, which is again labour intensive. Based on this, we decided on 
another approach to standardize and streamline the generation of an osteogenic graft.  
 
The aim of the work described in this manuscript is to further streamline the generation 
of osteogenic grafts by using volume of bone marrow rather than the concentration of 
nucleated cells in the bone marrow as a guiding parameter. This facilitates the clinical 
translation without affecting the bone forming potential of the engineered constructs. We 
demonstrate that within the same total culture time frame, a defined volume of fresh 
unprocessed bone marrow seeded directly on scaffolds in a static set up, could 
reproducibly produce grafts with similar osteogenic potential as those obtained by 
seeding and culturing 2D expanded cells.  
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2. Materials and methods 
2.1. Bone marrow aspirates 
Bone marrow aspirates (10-25 ml total volume) were obtained from 4 healthy donors 
during hip replacement surgery (donor information in Table 1) with written informed 
consent. Part of the bone marrow was used to isolate and proliferate hMSCs in 2D  on 
tissue culture plastic [30] while the rest of the bone marrow was directly seeded onto the 
scaffolds. 
 
2.2. 2D isolation and expansion of cells  
hMSCs were isolated and proliferated from the start of the culture period in hMSC 
osteogenic medium comprising (α-Modified Eagles Medium, Gibco) supplemented with 
10% foetal bovine serum (FBS, Lonza), 0.2 mM ascorbic acid (Sigma), 2 mM L-
glutamine (Gibco), 100 units/ml Penicillin (Gibco), 100 µg/ml Streptomycin (Gibco) and 
10-8 M dexamethasone (Sigma) to commit the cells towards the osteogenic lineage [31].  
To isolate the hMSCs on tissue culture plastic, aspirates were resuspended using a 20 
gauge needle, plated on tissue culture flasks at a density of 500,000 cells per square 
centimetre and cultured in hMSC osteogenic medium. Cells were grown at 37°C in a 
humid atmosphere with 5% CO2. Medium was changed after 5 days at which moment all 
the non-attached cells were removed. Thereafter, medium was refreshed twice a week for 
a total period of 2 weeks. The cells were then trypsinised, counted and seeded at a density 
of 200,000 cells/porous biphasic calcium phosphate scaffolds (kindly provided by Dr. 
Huipin Yuan, University of Twente, The Netherlands) produced according to the H2O2 
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method including naphthalene as described previously [32]. The material was sintered at 
1300 °C.  The average size of the granules was 2-3 mm with the specific surface area 
being 0.2 m2/g. The composition of the particles is 20TCP/80HA. The microporosity 
(volume percentage of micropores smaller than 10 µm within the ceramic) is 8.7% while 
the calcium release is 4.2 ± 0.4 ppm. 
 
2.3. Direct seeding of bone marrow on scaffolds  
For direct seeding, 200 µl of unprocessed bone marrow was gently dispersed over the 
surface of 3, 2-3 mm (BCP) scaffolds. After 4 hours, 2 ml of osteogenic medium was 
slowly added to each set of 3 scaffolds. Medium was changed after 5 days, and the cells 
were cultured for 3 weeks on the BCP scaffolds with regular medium change. As a 
control, expanded cells from the same donor were trypsinised after a 2 week culture 
period on tissue culture plastic. 200 µl aliquots were then made such that each aliquot 
contained 600,000 cells. The cells were then dispersed slowly over the surface of the 3 
scaffolds. After 4 hours, osteogenic medium was slowly added to the scaffolds. The 
expanded cells were cultured on these scaffolds for a period of 1 week with one medium 
change after 3 days.  
 
2.4. Cell proliferation, distribution, viability and cell morphology on scaffolds 
Cell numbers on the scaffolds were qualitatively assessed at the end of week 1, 2 and 3 of 
the culture period by methylene blue (MB) staining. Cells were fixed with 1.5% 
glutaraldehyde in 0.14 M cacodylic buffer, pH 7.3. After fixation, 1% MB solution 
(Sigma) was added and incubated for 60 seconds. The scaffolds were washed twice with 
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PBS in order to remove non-bound MB. Attached cells were visualized using light 
microscopy. A quantitative assessment of the number of cells on scaffolds was obtained 
by determining the DNA content on the scaffolds from both conditions using the Cyquant 
cell proliferation assay kit (Molecular Probes, Invitrogen detection techniques) according 
to the manufacturer’s instructions. For cell viability 3-(4, 5-dimethylthiazol-2-yl)-2, 5-
diphenyltetrazolium bromide (MTT) (Sigma) staining was used. A solution of 1% MTT 
was applied to the scaffolds containing cells. After 4 h of incubation, the MTT solution 
was removed by flushing the scaffolds with PBS. Scaffolds and cells were visualized 
using light microscopy. The morphology of the cells was studied using scanning electron 
microscopy (SEM). Scaffolds seeded directly with bone marrow and with 2D expanded 
cells were fixed in 4% paraformaldehyde, dehydrated with a series of graded ethanol 
washes and critical point dried with liquid CO2. Fixed scaffolds were sputtered with gold 
and examined. 
 
2.5. Cell Characterization 
The cells were characterized by immunostaining with antibodies against CD105 
(Endoglin; Dako), CD31 (PECAM-1; Dako) and CD45 (leukocyte common antigen; 
Dako). The scaffolds were fixed in 10% formalin, embedded in agarose, decalcified using 
2% formic acid for 24 hours and then embedded in paraffin. The paraffin samples were 
sectioned at 5 µm, mounted to the slide, deparaffinised and rehydrated.  For staining with 
CD31, antigen retrieval was performed by boiling the slides in sodium citrate buffer pH 
6.0 for 20 minutes. No antigen retrieval was required for CD45 whereas pre-treatment of 
the sections with proteolytic enzymes was performed prior to staining with CD105. The 
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sections were blocked using 1% BSA (Sigma) in PBS.  Primary antibody incubation was 
performed for 1 hour in humidified chambers using 1:10 dilution of either monoclonal 
mouse anti-human CD105, CD31 or CD45. Next, the endogenous peroxidise activity was 
blocked and the slides were incubated with goat anti mouse HRP conjugated secondary 
AB (Immunologic).  The cells were counterstained with haematoxylin and eosin to stain 
the cytoplasm and nuclei of cells. The slides were visualised with a light microscope 
(Leica). Immunostaining was performed on a total of 54 sections obtained from scaffolds 
seeded directly and with 2D expanded cells from donor 1, 2 and 3.  Thus, there were 3 
sections per antibody per condition for each of the 3 donors.   
 
2.6. In Vivo studies 
To compare the amount of bone formed by either direct seeding of bone marrow or 
seeding of 2D - expanded bone marrow cells, in vivo studies were designed in ectopic 
locations in immune-deficient mice, a model widely used for assessing bone forming 
capacity of hMSCs [7, 33-36]. The total culture time for the cells in both the direct 
seeding and the 2D expanded seeding was kept at 3 weeks. In the former, the cells were 
on the scaffolds from the start while in the latter they were first cultured for 2 weeks on 
plastic and then transferred to the scaffolds.  Prior to in vivo implantation, some scaffolds 
were used to stain with MB to confirm the presence of cells on the surface of the 
scaffolds.  Six immune-deficient male mice (Hsd-cpb:NMRI-nu, Harlan) were used for 
the first donor and 6 immune-deficient male mice (Crl:NMRI-Foxn1-nu-,Charles river) 
were used for each of the last three donors. The mice were anesthetized by inhalation of 
isoflurane and oxygen. Two subcutaneous pockets were made and each pocket was 
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implanted with 3 scaffolds, of each condition. The incisions were closed using a vicryl 5-
0 suture. After 6 weeks the mice were sacrificed using CO2 and samples were explanted. 
The experiments were approved by the local animal experimental committee. 
 
2.7. Bone Histomorphometry  
The explanted samples were fixed in 4% paraformaldehyde and embedded in 
methacrylate (L.T.I, Bilthoven, The Netherlands) for sectioning.  Approximately 300 µm-
thick, undecalcified sections were processed on a histological diamond saw (Leica saw 
microtome cutting system). At least 6 sections were made from each sample and the 
sections were stained with basic fuchsin and MB to visualize new bone formation.  The 
newly formed mineralized bone stains red with basic fuchsin while all other cellular 
tissues stain light blue with MB, and the ceramic material remains black and unstained by 
both the dyes. Histological sections were qualitatively analysed using light microscopy 
(Leica), and each histological section was scored either positive or negative for bone 
formation. Quantitative histomorphometry was performed as described previously [7]. 
Briefly, sections were scanned using Minolta Dimage Scan and high-resolution digital 
photographs (300 dpi) were made from three randomly selected sections from each 
tissue-engineered graft. For histomorphometrical analysis, bone and material were 
pseudo-coloured green and red, respectively, using Photoshop CS2 (Adobe Systems). 
Image analysis was performed using a PC-based system with KS400 software (version 3, 
Zeiss). A custom-made programme was used to measure bone/ceramic surface ratios. 
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3. Results 
We were interested in assessing the feasibility of using unprocessed bone marrow for 
direct seeding on scaffolds for bone tissue engineering applications. To do so, we 
performed studies to determine the volume of unprocessed fresh bone marrow, which 
when cultured on scaffolds for 3 weeks, reliably and reproducibly generated tissue 
engineered constructs with cell numbers and in vivo bone forming potential similar to 
that obtained by seeding 2D expanded cells. For all the studies performed, our aim was to 
have a scaffold covered with a confluent layer of cells.  
 
3.1. hMSC expansion on 3D scaffolds 
We first aimed at determining the possibility of growing hMSCs directly on scaffolds 
using unprocessed fresh bone marrow. To do this, we dispersed 1 ml of fresh, 
unmanipulated bone marrow directly onto 3 BCP scaffolds. After a week, we examined 
the presence of cells using MB and tested their viability using a MTT assay. Already after 
one week of culture, we observed foci of cells growing on the ceramics (fig 1A) and after 
three weeks of culture, the surface of the scaffold was completely covered by viable cells 
(Fig 1C, Fig 1D) similar to the condition where expanded cells were allowed to grow on 
the scaffolds for one week (Fig 1E, F). Our results show that it is possible to grow cells 
directly on scaffolds using fresh unmanipulated bone marrow. We then tried to determine 
the amount of bone marrow required to yield a cell sheath on the scaffolds after 3 weeks 
in culture. We chose a 3 week period because that is the time required to produce an 
osteogenic graft with 2 weeks of culture on plastic and one week on the scaffolds. We 
conducted studies with hMSCs derived from 8 different donors and the volumes of bone 
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marrow used for seeding ranged from 50 µl to 1 ml with varying concentrations of 
nucleated cell counts (see table 2).  Different volumes of bone marrow from different 
donors are dispersed over the scaffolds and after an initial 4hours incubation period the 
osteogenic medium was added. The scaffolds were left in culture for a period of 3 weeks. 
Cells were stained at weekly intervals (Fig 2). An average of 200 µl of bone marrow per 
3 scaffolds produced a confluent cell sheath. Lower volumes did not form a cell sheath in 
3 weeks while using higher volumes either did not provide significant benefits or led to 
detachment of the cell sheath from the scaffold surface (Fig 2)  
 
Based on these results, we used 200 µl of unprocessed bone marrow per 3 scaffolds with 
a 3 week culture period for all our experiments. To compare the direct seeding method 
with the conventional approach using 2D expanded cells, 600,000 2D expanded cells 
were seeded per 3 scaffolds.  In our experience, this number results in a confluent layer of 
cells on the scaffolds after 1 week [11, 37]. 
 
3.2. Cell quantification and viability 
We quantified the number of cells present on the scaffolds seeded directly with bone 
marrow to those seeded with 2D expanded cells using the Cyquant assay. In two of the 
three donors tested, the number of cells was similar on both scaffolds (Fig 3). In only one 
of the donors, two times more cells were found on the scaffolds seeded with 2D -
expanded cells as compared to those seeded directly with bone marrow. In all the 4 
donors, the viability of the cells present on the scaffolds was tested using the MTT assay. 
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This test confirmed that most of the cells in all 4 donors and in both conditions were 
metabolically active at the time of in vivo implantation (Fig 1D, 1F). 
 
3.3. Cell characterization 
Scanning electron microscopy of the ceramics at the end of the 3 week culture period 
demonstrated that all cells on the scaffolds seeded with 2D expanded cells had a 
fibroblastic morphology (Fig 4B). In contrast, on the scaffolds directly seeded with bone 
marrow, we noted the presence of spheroidal cells interspersed by predominantly 
fibroblastic cells (data not shown), suggesting that during direct seeding of bone marrow, 
populations of cells other than MSCs grew on the scaffold. To identify the population of 
cells on the ceramics from both groups, we performed immunostaining using antibodies 
against cells of mesenchymal (CD105), endothelial (CD31) and hematopoietic (CD45) 
lineage. For immunostaining, 3 scaffolds were included in the direct seeded and 2D 
expanded groups each and sections were obtained from each scaffold.  3 sections from 
every scaffold were stained for each of the 3 antibodies, i.e. CD31, CD45 and CD105.  In 
the sections from scaffolds seeded with 2D expanded cells, we observed no positive 
staining for CD31 or CD45 (Fig 4c). When stained with the CD 105 antibody, we 
observed a sheath of positively stained cells, indicating that all the cells on the scaffold 
were of mesenchymal origin (Fig 4d). In contrast, on scaffolds seeded directly with bone 
marrow we observed on average, 2-3 clusters of 3-4 cells positive for CD45 in each of 
the scaffold sections stained for CD45 (Fig 4a). CD31 positive cells, however, were not 
observed in all sections. In the sections stained for CD31, 0-2 CD31 positive cells were 
observed per section (Fig 4b). However, the majority of the cells on the direct seeded 
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scaffolds stained positive for CD105.  In conclusion, as compared to scaffolds seeded 
with 2D expanded cells, directly seeded scaffolds have a more heterogeneous cell 
population. However, in spite of the heterogeneity, the majority of the cells on the 
directly seeded scaffolds are MSCs, confirming our hypothesis that despite the very low 
numbers of MSCs in unprocessed bone marrow, this population of cells directly adheres 
and expands on the scaffold surface  
 
3.4. In Vivo Bone Formation 
To evaluate the bone forming capacity of the constructs, we implanted them for a period 
of 6 weeks in subcutaneous pockets in immune-deficient mice. Upon explantation, bone 
formation was analysed histomorphometrically. In the explanted samples from all 4 
donors, except  in those obtained from direct seeding of bone marrow from donor 1, 
histological examination revealed the presence of bone tissue, in which we observed 
osteocytes embedded in a mineralized extracellular matrix (Fig 5A). As seen before, the 
amount of bone obtained differs between different donors [11]. In donor 2, the 
bone/ceramic surface ratio increased from 0.14% in the scaffolds seeded with 2D 
expanded cells to 0.6% in those seeded directly with bone marrow and in donor 3 from 
0.20% in scaffolds seeded with 2D expanded cells to 0.37% in those seeded directly with 
bone marrow (Fig 5B). However, the results were not statistically significant when 
compared with Student’s paired t test (p>0.05%). Donor 4 performed the best in terms of 
bone formation. In this donor, the bone/ceramic surface ratio significantly increased from 
2.6% in the scaffolds seeded with 2D expanded cells to 7.7% in the scaffolds directly 
seeded with bone marrow (Fig 5B). This donor showed a significant benefit from the 
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direct seeding approach (p<0.05% using Student’s paired t test). When data from all the 4 
donors was combined, the average percentage bone/ceramic surface ratio increased from 
0.67 to 2.18.  Although not statistically significant, the direct seeding method shows a 
trend toward increased bone formation in vivo compared to the 2D method. For practical 
purposes, the results indicate that the direct seeding method using unprocessed bone 
marrow is at least as efficient in generating bone tissue upon implantation. 
 16
 
4. Discussion 
In the present study, we provide proof of principle on using pre-determined volumes of 
unprocessed bone marrow to generate grafts which have similar osteo-inductive potential 
as those produced within the same culture period, by seeding of MSCs derived from the 
same donor using the labour intensive 2D expansion.  
 
In 1987, Friedenstein et al. demonstrated the osteogenic potential of bone marrow derived 
MSCs, which led to the idea that hMSCs can be used to regenerate bone defects.  In spite 
of all the interest this idea generated, a quarter of a century later, hMSCs are still not 
available to the surgeons as a routine off the shelf treatment option [38]. One of the 
plausible reasons is that human bone marrow derived MSCs have very high donor to 
donor variability which cannot be predicted a priori. This translated into problems 
obtaining reproducible amounts of bone using MSCs, both in ectopic and orthotopic 
locations, thus limiting their use in clinical trials. The other limiting factor is the lack of 
standardized methods to generate grafts which, in addition to being cost efficient, are user 
friendly and do not require laboratory trained manpower and expensive equipment within 
the hospital set up. In this study we tried to address the second limiting factor. Proof of 
principle was found previously, when nucleated cell from minimally processed marrow 
was seeded onto scaffolds within a closed bioreactor with ectopic bone formation in vivo 
[23, 24]. Our approach of seeding scaffolds directly with unprocessed pre-determined 
volumes of bone marrow simplifies the process of generating osteogenic grafts even 
further. A similar approach of directly seeding bone marrow on scaffolds was also used 
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by other researchers in the past to generate bone in a critical size defect with limited 
success [39] [40]. One of the main differences in their strategy as compared to ours was 
that in all these studies the scaffolds seeded with bone marrow were implanted within an 
hour (referred to as per-operative cell seeding). We have already demonstrated the poor 
performance of per-operative seeding even with 2D expanded cells [40]. Evidently 
expansion of MSCs prior to implantation is necessary. In this manuscript, MSC 
expansion occurred on scaffolds in a static environment in well plates whereas 
bioreactors were used by previous researchers to culture the scaffolds in a dynamic 
environment. Although commercially viable, automated systems are still not available for 
routine hospital use [41], the direct seeding approach can be adapted for use within a 
bioreactor set up. 
 
 Previously researchers used nucleated cell counts as a guide to assess the population of 
CFU-Fs in the bone marrow. In our in vivo study, instead of using nucleated cell counts, 
an average volume of bone marrow was used in all the four donors as a practical readout. 
Although the nucleated counts were obtained, they were not taken into consideration 
when seeding the scaffold. In retrospect, we observe that donor 1 which had the lowest 
nucleated cell count (Table 1) performed worst in the in vivo setting and donor 4 with the 
highest nucleated cell count performed the best. In contrast, although donor 3 had a much 
higher nucleated cell count than donor 2, still directly seeded scaffolds in donor 2 gave 
more bone than donor 3. In general there was no definite correlation between the amount 
of bone formed and the initial number of nucleated cells in the bone marrow. This is in 
agreement with literature, which suggests that nucleated cell counts do not indicate CFU-
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Fs present in a particular amount of bone marrow [42].  One may argue that a pre- 
determined amount of bone marrow is also not a fool proof method of ensuring a cell 
scaffold construct with osteogenic potential thereby warranting additional quality control 
criteria in future studies. Markers such as STRO-1 and NGF currently available may 
prospectively determine the number of CFU-Fs in the bone marrow. Nevertheless, in our 
study using predetermined volumes of bone marrow as in the 8 donors with varying 
nucleated cell counts that we studied, we were able to obtain a complete coverage of the 
scaffolds in 3 weeks using 200 µl of bone marrow per 3 scaffolds, in all the donors.  
 
It can be argued that using the 2D expansion method for greater than 2 weeks as used in 
this study, a larger number of cells could be obtained and this in turn could support 
generation of larger osteoinductive constructs. However it has been reported in literature 
that 2D expanded bone marrow derived hMSCs have a much lower differentiation 
capacity as compared to the MSCs found in fresh bone marrow. Repeated passaging of 
cells can eventually lead to their senescence [43-45]. Moreover, 20-40 ml of bone 
marrow can be obtained safely from patients [30]. This can generate as much as 8 to 13 
cc of graft material which would be sufficient for most routine clinical applications. 
Further, here we chose a period of 3 weeks as the culture period as we wanted to compare 
our findings with scaffolds seeded with 2D expanded cells. However, depending on the 
application, the culture period and the amount of bone marrow used per scaffold can be 
modified.  
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Based on the results of this study and using this approach of direct seeding, we are now 
testing a prototype of a compact, closed, sterile system which is pre-packed with 
scaffolds and which could be used in the clinics without the need for trained personnel or 
special sterile work areas. This device in combination with the direct seeding approach 
can thus be utilised by a surgeon directly within the surgical theatre and then left for the 
culture duration in an incubator routinely present in most hospitals. 
 
In conclusion, the direct seeding approach offers potential use in clinical situations. 
However, the osteogenicity of the grafts either using the conventional approach or the 
approach proposed in this work is not comparable as yet to the autologous bone grafts or 
that observed with MSCs derived from rat or goat. Further studies using supplementation 
of the medium with osteogenic factors should be considered to help address this issue. 
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Table 2  Donor information for optimization of volume of bone marrow to scaffold ratio 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Donor Age Sex 
Nucleated 
cell/ml x106 
1 65 Female 8.3 
2 72 female 26.6 
3 66 female 15 
4 60 Male 28 
5 71 Female 25 
6 45 Male 10.4 
7 69 Male 15.4 
8 83 Female 17.8 
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Figure Legends 
 
Fig 1. Cell proliferation and viability on porous ceramic scaffolds.  
Methylene blue staining of scaffolds seeded with unprocessed bone marrow after 1 (A), 2 
(B) or 3 (C) weeks of culture. The blue dots represent cells on the scaffold. MTT staining 
at week 3 of a scaffold seeded with unprocessed bone marrow (D). 
As a control, cells from the same donor were expanded and seeded on the scaffold and 
after 1 week stained for methylene blue (E) and MTT (F). To verify that scaffold by itself 
does not stain with methylene blue or MTT, a representative scaffold without cells was 
stained for methylene blue (G) and MTT (H).  
 
 Fig 2. Optimisation of volume of bone marrow to scaffold ratio    
Methylene blue staining of 1 scaffold from groups of 3 scaffolds seeded with 50 µl (A), 
100 µl (B), 200 µl (C), 400 µl (D), 800 µl (E), 1 ml (F) of unprocessed bone marrow, 
after 3 weeks of culture.  The blue dots represent cells on the scaffold while the arrow in 
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Fig E denotes a cell clump.  200 µl of bone marrow per 3 scaffolds gave optimum cell 
coverage on the scaffold surface while lower volumes did not form a cell sheath. Seeding 
higher volumes on the scaffolds resulted in the cell sheath detaching from the scaffold 
surface. Arrow in figure F denotes the detaching cell sheath.    
 
Fig 3. Quantification of cell growth.  
Estimation of DNA content to quantify the number of cells present on scaffolds cultured 
with either unprocessed bone marrow (DS) or 2D expanded cells (2D).  In two of the 
three donors tested, the number of cells was similar in both groups. In donor 3, 2 times 
more cells were found on scaffolds seeded with 2D expanded cells as compared to those 
seeded directly with unprocessed bone marrow.  
 
Fig 4.  Characterization of cells on ceramic scaffolds 
Immunostaining with CD45, CD31 and CD105 antibodies on ceramic scaffolds. Brown 
staining of membrane indicates cells positive for the antibody while blue dots represent 
the nucleus of the cells.  Clusters of CD45 positive cells (A) and CD31 positive cells (B) 
on scaffolds seeded with unprocessed bone marrow. Both CD 45 and Cd 31antibody 
staining was negative on scaffolds seeded with 2D expanded cells (C). On staining with 
CD105, a positively stained cell sheath is noted on scaffolds seeded with unprocessed 
bone marrow (D). Similar results were observed with scaffolds seeded with 2D expanded 
cells. On scanning electron microscopy of scaffolds seeded with 2D expanded cells, all 
cells had a similar morphology indicating presence of cells of the same lineage (E).  
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Fig 5. Bone formation on porous ceramic scaffolds 
(A). Representative histological section of scaffolds directly seeded with bone marrow 
and implanted in vivo for 6 weeks prior to staining with basic fuschin and methylene 
blue. This representative image shows newly formed bone (red with blue arrow), 
osteocytes embedded in matrix (black arrow) and the scaffold (white arrow). (B). Bar 
graph comparing the amount of bone formed by scaffolds seeded directly or with 2D 
expanded cells from the bone marrow of 4 donors. The data was analysed using Students 
paired T test.  
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